Name (Synonyms) | Correlation | |
---|---|---|
drug858 | Toraymyxin PMX-20R (PMX Cartridge) Wiki | 0.50 |
drug407 | ICU treatment Wiki | 0.50 |
drug862 | Transpulmonary thermodilution Wiki | 0.50 |
drug275 | Echocardiography Wiki | 0.35 |
drug582 | Oseltamivir Wiki | 0.22 |
drug82 | Azithromycin Wiki | 0.11 |
drug360 | Hydroxychloroquine Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D012770 | Shock, Cardiogenic NIH | 0.50 |
D012772 | Shock, Septic NIH | 0.50 |
D019446 | Endotoxemia NIH | 0.50 |
D018805 | Sepsis NIH | 0.50 |
D018487 | Ventricular Dysfunction, Left NIH | 0.35 |
D018754 | Ventricular Dysfunction NIH | 0.35 |
D000860 | Hypoxia NIH | 0.17 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
D016638 | Critical Illness NIH | 0.13 |
D055371 | Acute Lung Injury NIH | 0.08 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D014777 | Virus Diseases NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
There are 4 clinical trials
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.
Description: Body temperature(°C)
Measure: Body temperature Time: Through study completion, an estimation of 6 monthsDescription: Blood pressure in mmHg
Measure: Blood pressure Time: Through study completion, an estimation of 6 monthsDescription: Pulse (heart rate) in times/minute
Measure: Pulse (heart rate) Time: Through study completion, an estimation of 6 monthsDescription: Respiratory rate in times/minute
Measure: Respiratory rate Time: Through study completion, an estimation of 6 monthsDescription: Cardiac index (L/min/m2)
Measure: Data provided by transpulmonary thermodilution-CI Time: Through study completion, an estimation of 6 monthsDescription: Global end-diastolic volume(mL/m2)
Measure: Data provided by transpulmonary thermodilution-GEDV Time: Through study completion, an estimation of 6 monthsDescription: Extravascular lung water (mL/kg)
Measure: Data provided by transpulmonary thermodilution-EVLW Time: Through study completion, an estimation of 6 monthsDescription: Pulmonary vascular permeability index
Measure: Data provided by transpulmonary thermodilution-PVPI Time: Through study completion, an estimation of 6 monthsDescription: Left ventricle ejection fraction, Segmental left ventricle contractility, Speckle tracking data of the left and right ventricles, Dimensions of right and left cavities and Diastolic function of left ventricle
Measure: Incidence of new-onset or reversible systolic left ventricular dysfunction Time: Through study completion, an estimation of 6 monthsDescription: The worst extravascular lung water
Measure: Changes of extravascular lung water measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsDescription: The worst pulmonary vascular permeability index
Measure: Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsProspective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
The Risk stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry was founded during the emerging SARS-CoV-2 pandemic. COVID-19 is a novel disease caused by infection with the SARS-CoV-2 virus that was first described in December 2019. The disease has spread exponentially in many countries and has reached global pandemic status within three months. According to first experience, hospitalization was required in approximately 20 % of cases and severe, life-threatening illness resulted in approximately 10 %. In some countries, health care systems were overwhelmed by the rapid increase in critically ill patients that far exceeded their capacity. It is thus of utmost importance to gain knowledge about the characteristics and course of critically ill patients with COVID-19 and to stratify these patients according to their risk for further deterioration. A key part of fighting this pandemic is to exchange scientific information and advance our understanding of the disease. The Risk stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry aims to collect an anonymized dataset to characterize patients that develop life-threatening critical illness due to COVID-19 and make it accessible to collaborative analysis. The data collected may be composed of a core dataset and/or an extended dataset. The core dataset consists of a basic set of parameters, of which many are commonly generated during treatment of critically ill patients with COVID-19 in an intensive care unit (the individual parameters are marked yellow in the attached case report forms, and are clearly marked on the electronic case report forms during data entry). The extended dataset consists of parameters that may be measured during treatment of critically ill patients with COVID-19 in an intensive care unit, depending on clinical practice, indication and availability of the measurement method. The data accumulating in the registry as the pandemic or subsequent waves develop are made available to the collaborators to support an optimal response to the pandemic threat. The information gained on the initial characteristics and disease course via the RISC-19-ICU registry may contribute to a better understanding of the risk factors for developing critical illness due to COVID-19 and for an unfavorable disease course, and thus support informed patient triage and management decisions. Initial research questions are (I) to perform risk stratification of critically ill patients with COVID-19 to find predictors associated with the development of critical illness due to COVID-19: characterization of the study population, which are critically ill patients with COVID-19: inflammation, oxygenation, circulatory function, among other parameters collected in the registry, and (II) to perform risk stratification of critically ill patients with COVID-19 to predict outcome after ICU admission (ICU mortality, ICU length of stay): characterization of patients grouped by disease course in the ICU, based on inflammation, oxygenation, circulatory function, and other parameters collected in the registry.
In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide. Indeed, SARI had a relevant role in the development of pandemic and epidemic with terrible consequences such as the 2009 H1N1 pandemic which led to more than 200.000 respiratory deaths globally. In late December 2019, in Wuhan, Hubei, China, a new respiratory syndrome emerged with clinical signs of viral pneumonia and person-to-person transmission. Tests showed the appearance of a novel coronavirus, namely the 2019 novel coronavirus (COVID-19). Two other strains, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused severe respiratory illnesses, sometimes fatal. In particular, the mortality rate associated with SARS-CoV and MERS-CoV, was of 10% and 37% respectively. Even though COVID-19 appeared from the first time in China, quickly it spread worldwide and cases have been described in other countries such as Thailand, Japan, South Korea, Germany, Italy, France, Iran, USA and many other countries. An early paper reported 41 patients with laboratory-confirmed COVID-19 infection in Wuhan. The median age of the patients was 49 years and mostly men (73%). Among those, 32% were admitted to the ICU because of the severe hypoxemia. The most associated comorbidities were diabetes (20%), hypertension (15%), and cardiovascular diseases (15%). On admission, 98% of the patients had bilateral multiple lobular and sub-segmental areas of consolidation. Importantly, acute respiratory distress syndrome (ARDS) developed in 29% of the patients, while acute cardiac injury in 12%, and secondary infection in 10%. Invasive mechanical ventilation was required in 10% of those patients, and two of these patients (5%) had refractory hypoxemia and received extracorporeal membrane oxygenation (ECMO). In a later retrospective report by Wang and collaborators, clinical characteristics of 138 patients with COVID-19 infection were described. ICU admission was required in 26.1% of the patients for acute respiratory distress syndrome (61.1%), arrhythmia (44.4%), and shock (30.6%). ECMO support was needed in 11% of the patients admitted to the ICU. During the period of follow-up, overall mortality was 4.3%. The use of ECMO in COVID-19 infection is increasing due to the high transmission rate of the infection and the respiratory-related mortality. Therefore, the investigators believe that ECMO in case of severe interstitial pneumonia caused by COVID could represent a valid solution in order to avoid lung injuries related to prolonged treatment with non-invasive and invasive mechanical ventilation. In addition, ECMO could have a role for the systemic complications such as septic and cardiogenic shock as well myocarditis scenarios. Potential clinical effects and outcomes of the ECMO support in the novel coronavirus pandemic will be recorded and analyzed in our project. The researchers hypothesize that a significant percentage of patients with COVID-19 infection will require the utilize of ECMO for refactory hypoxemia, cardiogenic shock or septic shock. This study seeks to prove this hypothesis by conducting an observational retrospective/prospective study of patients in the ICU who underwent ECMO support and describe clinical features, severity of pulmonary dysfunction and risk factors of COVID-patients who need ECMO support, the incidence of ECMO use, ECMO technical characteristics, duration of ECMO, complications and outcomes of COVID-patients requiring ECMO support.
Description: age in years
Measure: Age Time: at baselineDescription: male/female
Measure: Gender Time: at baselineDescription: in kilograms
Measure: Weight Time: at baselineDescription: in meters
Measure: Height Time: at baselineDescription: weight and height combined to calculate BMI in kg/m^2
Measure: BMI Time: at baselineDescription: Asthma y/n, cystic fibrosis y/n, chronic obstructive pulmonary disease y/n, pulmonary hypertension y/n, pulmonary fibrosis y/n, chronic restrictive lung disease y/n
Measure: Pre-existing pulmonary disease y/n Time: at baselineDescription: diabetes mellitus y/n, chronic renal failure y/n, ischemic heart disease y/n, heart failure y/n, chronic liver failure y/n, neurological impairment y/n
Measure: Main co-morbidities y/n Time: at baselineDescription: in dd-mm-yyyy or mm-dd-yyyy
Measure: Date of signs of COVID-19 infection Time: at baseline or date of occurenceDescription: in dd-mm-yyyy or mm-dd-yyyy
Measure: Date of positive swab Time: at baseline or date of occurenceDescription: in days
Measure: Pre-ECMO length of hospital stay Time: at or during ECMO-implantDescription: in days
Measure: Pre-ECMO length of ICU stay Time: at or during ECMO-implantDescription: in days
Measure: Pre-ECMO length of mechanical ventilation days Time: at or during ECMO-implantDescription: y/n, what kind
Measure: Use of antibiotics Time: up to 6 monthsDescription: y/n, what kind
Measure: Use of anti-viral treatment Time: up to 6 monthsDescription: y/n, what kind (eg prone-position, recruitment manoeuvers, neuromuscular blockade etc)
Measure: Use of second line treatment Time: up to 6 monthsDescription: respiratory or cardiac
Measure: Indications for ECMO-implant Time: at ECMO-implantDescription: veno-venous, veno-arterial or veno-venoarterial
Measure: Type of ECMO-implant Time: at ECMO-implantDescription: peripheral or central
Measure: Type of access Time: at ECMO-implantDescription: in dd-mm-yyyy or mm-dd-yyyy
Measure: Date of ECMO implant Time: at ECMO-implantDescription: l/min
Measure: ECMO blood flow rate Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 monthsDescription: l/min
Measure: ECMO gas flow rate Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 monthsDescription: y/n
Measure: ECMO configuration change Time: up to 6 monthsDescription: in dd-mm-yyyy or mm-dd-yyyy
Measure: Date of ECMO configuration change Time: up to 6 monthsDescription: veno-venous, veno-arterial, veno-venoarterial, other
Measure: New ECMO configuration Time: up to 6 monthsDescription: right ventricular failure, left ventricular failure, refractory hypoxemia
Measure: Indications for ECMO configuration change Time: up to 6 monthsDescription: settings of ventilator
Measure: Ventilator setting on ECMO Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 monthsDescription: heparin, bivalirudin, nothing
Measure: Anticoagulation during ECMO Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 monthsDescription: amount of ECMO circuit changes (1, 2, 3 etc.)
Measure: Frequency of ECMO circuit change Time: up to 6 monthsDescription: Hemorrhagic, infection, other complications
Measure: ECMO complications Time: up to 6 monthsDescription: y/n
Measure: ECMO Weaning Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 monthsDescription: y/n, date
Measure: ICU discharge Time: from day of ICU-admission for every 24 hours until date of discharge or death, up to 6 monthsDescription: Ward, another ICU, rehabilitation center, home
Measure: Type of discharge Time: up to 6 months